The effect of digital medicine on diagnostics is having and will continue to have a revolutionary effect on the interactions between patients and their healthcare providers and between the healthcare system and its service and support providers. While these changes herald more streamlined and to some extent personalized treatments for patients, the dynamic of these relationships will also have profound effects on treatment decisions. We examine the factors digital medicine companies face in gaining market access.
Moderator: Josep Sanfeliu – Ysios Capital
Michäel Herman – OncoDNA
Jeremy Sohn – Novartis
Gregg Talbert – Roche Partnering